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Summary
 
Background
 
High calcitonin (CT) serum levels suggest metastatic
spread in medullary thyroid carcinoma (MTC) after thyroidectomy.
In  limited disease stages, however, morphological investigations
including ultrasound, magnetic resonance imaging (MRI) and 18F-
FDG positron emission tomography ([18F]FDG-PET) may often fail
to identify exact tumour sites.
 
Objective
 
The aim of the present study was to establish an improved
strategy to identify small cervical tumours by combining pentagastrin
stimulation with bilateral cervical intravenous CT sampling followed
by high-resolution ultrasound.
 
Design and patients
 
Six MTC patients were examined, of whom
ﬁve patients already had bilateral neck dissection. Five patients had
sporadic MTC, and one patient suffered from MEN2a.
 
Results
 
Retrospective analysis of all patients revealed a highly
sensitive positive correlation between an early calcitonin peak (20–40 s
after pentagastrin injection) and site of cervical tumour affection.
Postinterventional ultrasound examination of the affected regions of
the neck revealed suspicious presence; in some cases small lymph nodes
of less than 1 cm in size were then surgically excised. On histology,
small tumours could be identiﬁed in four patients. Postsurgical
examination revealed a clear decline of basal serum calcitonin levels
in four patients (between 
 
−
 
41% and 
 
−
 
100%). In two patients CT
normalized to baseline levels (< 10 pg/ml) and in another two
patients CT rendered to near normal (14 and 17 pg/ml).
 
Conclusion
 
Pentagastrin stimulation-based intravenous catheter
sampling may be beneﬁcial in the diagnostic work-up of MTC after
thyroidectomy. Our data show that an early calcitonin peak (20–40 s after
administration of pentagastrin) helps to identify tumour-affected regions.
(Received 4 August 2006; returned for revision 10 September 2006; 
 
ﬁnally revised 26 September 2006; accepted 2 October 2006)
 
Introduction
 
Medullary thyroid carcinoma (MTC) is a rare tumour derived from
the parafollicular calcitonin (CT)-secreting cells of the thyroid,
explaining the key role of CT as a speciﬁc and sensitive marker of
this cancer. MTC occurs in the sporadic form in about 70–80% of
cases, while the remaining 20–30% are due to inherited forms
 
1
 
including either isolated (familial MTC) or part of multiple endo-
crine neoplasia syndromes. Prognosis of MTC is relatively good
with a 10-year survival rate ranging from 47% to 78%
 
2,3
 
 and even
better in patients with CT doubling-time of more than 2 years.
 
4
 
Within the past decade the prognosis has improved mainly because
of earlier diagnosis and improvement in surgical procedures.
 
5,6
 
Nevertheless, more than 50% of nonprophylactic thyroidectomized
patients are not cured after surgery.
 
5
 
 In these cases residual tumour
cells can be detected by measuring serum calcitonin alone or in
combination with pentagastrin stimulation. In limited disease
stages imaging studies, including ultrasound and MRI often fail to
identify affected organs. [18F]FDG-PET has recently been proposed
to identify residual tumour masses.
 
7,8
 
 Nonetheless, this procedure
also has limitations as small tumours are rarely detected.
Conventional intravenous calcitonin sampling may identify tumour-
affected regions with larger tumour burden resulting in moderately
to highly elevated serum calcitonin levels; however, no micrometas-
tases with slightly increased calcitonin levels can be identiﬁed
either.
 
6,9–12
 
The aim of the present study was to investigate the prognostic
value of a combined diagnostic strategy to identify tumour-affected
areas. We here performed intravenous catheter CT sampling of
potentially affected areas with pentagastrin stimulation in parallel
followed by high-resolution ultrasound. On the basis of this approach
we could identify tumour-affected cervical regions that could then
be surgically revised.
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Subjects and methods
 
Subjects
 
Clinical data of all patients are summarized in Table 1. Five patients
with occult metastatic spread of previously diagnosed MTC were
examined. In these patients persistent MTCs were diagnosed by elevated
basal serum CT levels (normal < 10 pg/ml without previous thyroidec-
tomy) and pathological stimulation after administration of pentagastrin
(except Patient 5 with highly elevated basal CT levels). In all of these
patients distant metastases were excluded by performing computed
tomography.  Patient 4 suffered from multinodular goitre with
slightly elevated basal calcitonin levels including pathological
stimulation of CT after administration of pentagastrin. All but one
patient suffered from sporadic MTC. Patient 6 had multiple endocrine
neoplasia type 2a. This patient had suffered from bilateral pheochro-
mocytoma which had been surgically removed before. Five patients
(1, 2, 3, 5 and 6) already had, in some cases multiple, bilateral neck
dissections and lymphadenectomies. All previous operations were
performed by experienced surgeons, most of them at the Depart-
ment of Surgery at the University Hospital Duesseldorf in Germany.
 
Methods
 
Pentagastrin-stimulated calcitonin sampling.
 
Pentagastrin-stimulated
intravenous calcitonin sampling was performed before surgical
intervention. In each patient two intravenous catheters were placed
in the regions of interest, mostly in lower parts of both internal jug-
ular veins. Because of altered anatomy in Patient 5, both catheters
were  placed in the brachiocephalic veins. Body weight-adapted
(0·5 
 
µ
 
g per kg body weight) pentagastrin stimulation (Wallsend,
Cambridge, UK) was then performed using peripheral blood sam-
pling for control at baseline and 20 s, 40 s and 60 s after peripheral
pentagastrin stimulation and thereafter every 30 s for 4 min. Since
an interim analysis of Patient 1, 2 and 3 showed that sufﬁcient inter-
pretation can be reached by studying time-points for CT measure-
ment within the ﬁrst 120 s, the procedure was shortened in Patient
4, 5 and 6. In parallel, peripheral blood CT assessment was performed
in all patients for comparison.
 
Calcitonin assay.
 
A solid-phase, enzyme-labelled, two-site chemilu-
minescent immunometric assay was used for measurement of
calcitonin. The assay was performed as recommended by the
manufacturer (Immulite 2000, DPC, Bad Nauheim, Germany).
On the basis of this method only the intact mature form of CT was
detected. The detection level of the assay is 2 pg/ml. The intra- and
interassay coefﬁcients of variation were between 2·8% and 6·2%,
and 3·3 and 6·9%, respectively, for values ranging from 11·5 up to
1628·0 pg/ml.
 
Results
 
The pentagastrin stimulation-based intravenous CT sampling was
performed in six patients. Initially, the sampling was performed over
a time period of 270 s (Patient 1, 2 and 3). This procedure was short-
ened to 120 s in Patient 4, 5 and 6. In all patients an early CT peak
could be detected on one cervical site at 20 s and at maximum 40 s
after peripheral intravenous administration of pentagastrin. This
cervical region was then considered as highly suspicious for presence
of remnant tumour cells. High-resolution ultrasound of the poten-
tially affected cervical region was then performed by an experienced
clinician and suspicious nodules were marked. In most cases, these
nodules were only few millimeters in size (< 10 mm). Because of the
size and other anatomical considerations, ﬁne needle aspiration was
not an option to be performed. Subsequently potentially affected
regions in all patients were surgically revised.
Based on the histological results, small MTCs were found in 4 out of
6 patients (Patients 2, 3, 4 and 5). All results correlated with the pre-
surgical predicted site of potential cervical tumour affection. In these
four patients a decline of basal serum CT could be detected (
 
−
 
39%
up to 
 
−
 
97%). Comparable results were seen in Patient 2, 3 and 4 after
intravenous stimulation with pentagastrin (
 
−
 
34% up to 
 
−
 
100%). In
one patient (Patient 4) the tumour could be completely removed,
whereas in Patient 5 only a slight increase of serum calcitonin could
be detected after stimulation with pentagastrin (maximum serum
calcitonin 26 pg/ml). This is crucial, for instance as in Patient 5,
no complete tumour exstirpation could be achieved even after
six operations. In Patient 4 with a multinodular goitre, without any
previous cervical operations we could predict where the tumour was
Table 1. Patient characteristics
Patient
Age (years), 
gender
Initial 
diagnosis
Type of 
MTC
Previous 
treatments
Before operation  After operation
Basal CT Stimulated CT Basal CT Stimulated CT
1 59, female 1998 sporadic TE, ND, LE(1) 48 pg/ml 431 pg/ml 47 pg/ml 579 pg/ml
2 41, female 1989 sporadic TE, ND, LE(2) 23 pg/ml 272 pg/ml 14 pg/ml 134 pg/ml
3 38, female 2003 sporadic TE, ND, LE(3) 41 pg/ml 527 pg/ml 17 pg/ml 242 pg/ml
4 64, male 2004 sporadic none 17 pg/ml 155 pg/ml < 5 pg/ml < 5 pg/ml
5 39, female 1994 sporadic TE, ND, LE(5) 226 pg/ml n.d. 7 pg/ml 26 pg/ml
6 44, male 1998 MEN2a TE, ND 10 pg/ml 700 pg/ml 31 pg/ml 1347 pg/ml
Type of medullary thyroid carcinoma (MTC): MEN2a, multiple endocrine neoplasia type 2a.
Previous treatments: TE, thyroidectomy; ND, bilateral neck dissection; LE, additional cervical lymphadenectomy (number of additional LEs); CT, calcitonin. 
Pentagastrin-stimulated intravenous calcitonin sampling
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located in the thyroid lobe. In Patient 2 and 3, the positive histology
correlated with a decline of postinterventional basal (
 
−
 
39% up to
 
−
 
59%) and stimulated calcitonin. However, CT levels were still
detectable after surgery. In Patient 6 with borderline basal serum CT
levels, neither tumour cells could be detected on histology and nor
did serum CT levels decline after surgical intervention. The same
observations were made in Patient 1 who had more elevated basal
CT levels.
 
Discussion
 
To  the best of our knowledge, this is the ﬁrst description of an in
general simple method to localize occult metastatic spread of med-
ullary thyroid carcinoma (MTC) by combining separated intra-
venous calcitonin sampling in parallel with pentagastrin stimulation.
Our data clearly show that an early calcitonin peak (about 20–40 s
after intravenous pentagastrin administration) collected in the
lower part of both jugular veins is a very strong indicator of residual
tumour tissue at the cervical site where the catheter is placed. Having
these results in mind a high-resolution ultrasound was performed
in each case by an experienced clinician and suspicious cervical
nodules were marked. Then targeted surgery by an experienced
surgeon was performed. Based on this approach, residual tumours
could be identiﬁed in four of six patients leading to a pronounced
decrease of serum calcitonin. To evaluate the efﬁcacy of this procedure
peripheral pentagastrin stimulation was also performed after
surgical intervention. On that basis, two of our patients could
be cured ‘biochemically’ as judged by basal serum calcitonin meas-
urements. After pentagastrin stimulation one of the two patients
showed no increase in serum calcitonin, whereas the other patient
revealed a slight increase. These results are absolutely crucial as
some of our patients had already undergone diverse surgical
interventions as in Patient 5, who had already experienced six
cervical operations including one bilateral neck dissection and ﬁve
lymphadenectomies.
A multitude of different imaging methods have already been studied
for the detection of residual tumour tissue in MTC. A fairly good
sensitivity of 93% with a speciﬁcity of 75% was achieved by MRI for
differentiation of a scar from recurrent tumour disease in the thyroid
bed.
 
13
 
 Scintigraphical methods have also been studied including
pentetreotide scintigraphy with a reported sensitivity between 37%
and 71%, respectively.
 
14–17
 
 Comparable results were also seen using
 
99m
 
Tc-V-DMSA with a sensitivity of 68% for imaging MTC metastases
 
18
 
as well as for CEA-antibodies labelled with 
 
111
 
In or 
 
99m
 
Tc with sen-
sitivities of around 60%.
 
19,20
 
 [18]FDG PET may play a complementary
role in tumour detection.
 
7
 
 The most sensitive method for localiza-
tion of a recurrent tumour mass or of lymph node metastases in the
neck is, however, conventional high-resolution ultrasound which
gives a sensitivity of around 96% and a speciﬁcity of 83%.
 
21
 
 None-
theless, if the maximum tumour size is a few millimeters only and
there are only slightly to moderately increased serum CT levels, the
tumours might not be detected by this method. Conventional selec-
tive venous catheterization may represent an additional method to
guide the surgeon to the cervical site that has to be operated on. This
method, however, only works if the tumour is large enough for detec-
tion of differences in serum CT on a basal level.
 
9
 
 In patients with
small tumour residues this method will fail to detect differences.
Using the combined strategy described here, there is a fairly good
chance to determine the cervical site on which the surgeon should
operate. Of note, one of our patients (Patient 4) had never under-
gone previous cervical operation and had just slightly increased
serum CT levels along with a pathological CT stimulation at the time
of presentation. Because of the patient’s wish, the procedure was also
offered to him after receiving informed consent. Based on our
results, we were able to predict which thyroid lobe was affected
by the tumour. If these data are conﬁrmed in a larger patient popu-
lation with sporadic MTC, operations strategies for very small
tumours (with only slightly elevated CT levels) might be altered in
the future. This procedure should, however, only be offered to
patients with slightly elevated basal and stimulated CT levels, and
not to patients with markedly increased CT levels or multinodular
goitre. Without an exact answer to this question, total thyroidectomy
along with bilateral lymph node dissection will remain the therapy
of choice.
In summary, the method described here may represent an alter-
native approach to identify tumour-affected cervical regions in
patients with metastasized MTC. This method may, however, only
be successful if the tumour is conﬁned to the neck on one cervical
site and with slightly to moderately elevated serum calcitonin levels
only. In patients with higher basal serum CT levels, differences might
not be detected. Based on our results we can recommend our work-up
strategy if patients have maximum calcitonin values of 100 pg/ml to
250 pg/ml. As mentioned above, the procedure itself is simple to plan
and the technical equipment is not sophisticated, as it only combines
intravenous catheter sampling with pentagastrin stimulation
followed by high-resolution ultrasound. On the other hand, the
blood drawings at three different localizations (the periphery and
both jugular veins or brachiocephalic veins, respectively) need to be
performed within precise time limits. To our experience, this can
only be performed with three physicians performing blood sampling
and another three persons assisting blood sampling. This might,
however, be worthwhile in patients where no exact identiﬁcation of
tumour areas has been reached despite a combination of several
imaging techniques (Fig. 1).
Calcitonin (CT) sampling was performed after pentagastrin
stimulation at both jugular veins and the periphery for comparison.
Because of altered anatomy, blood sampling in Patient 5 was per-
formed from both brachiocephalic veins as well as the periphery.
Initially, the sampling was performed over a time period of 270 s
(Patient 1, 2 and 3). The procedure was shortened to 120  s in
Patients 4, 5 and 6. In all patients an early CT peak could be detected
on one cervical site at 20 s and at maximum 40 s after peripheral
intravenous administration of pentagastrin. This cervical region
was then considered as highly suspicious for presence of remnant
tumour cells.
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